No Data
Morgan Stanley Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $55
UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
UBS Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $60
Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral
BofA Securities Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $65
No Data
No Data